Skip to main content
. Author manuscript; available in PMC: 2021 Nov 23.
Published in final edited form as: Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980

Figure 2. Improved glycemia in teplizumab treated participants is associated with maintenance of dysglycemic status.

Figure 2.

A. OGTT classifications for participants in each group over 36 months of follow-up. The data are shown to 36 months because of loss of placebo treated participants because of the clinical diagnosis of T1D (for individual participants see Supplemental Figure 2). B. Boxplot displaying median and interquartile ranges for on-study OGTT glucose AUC mean for participants from placebo and teplizumab treated groups. ANCOVA model incorporating baseline value, age, and treatment group showed that treatment group had a significant effect to decrease average on-study glucose AUC (ANCOVA teplizumab effect: 92.8%, p=0.03).